STIFEL 2026 HEALTHCARE CONFERENCE - BICARA THERAPEUTICS INC

Financial Performance:

• The company disclosed a cash balance of $442.3 million at the end of the quarter, sufficient to fund operations into early 2029.
• Capital allocation is prioritized to complete enrollment in the Fortify trial through the survival endpoint, initiate the Fortify Flex trial, support initial commercial infrastructure, and conduct signal-seeking work in other indications.
• No specific revenue, earnings, or profit margin data was reported as the company is in a clinical development phase without commercialized products.
• No debt was mentioned in the call commentary.

Guidance and Future Outlook:

• Topline data for the pivotal Phase 3 Fortify HNL1 trial (recurrent metastatic head and neck cancer) is anticipated in the middle of next year.
• Management has committed to conducting an interim analysis for overall survival; the timing will be determined by the accrual rate of death events in the HPV-negative population.
• The company anticipates the recurrent metastatic head and neck EGFR market to reach approximately $5 billion by 2030.
• Efficacy data for the colorectal cancer (CRC) program (3rd line setting) is accepted for presentation at ASCO GI in January.
• Long-term goal is to achieve a "best-in-class" overall survival profile driven by the depth and durability of response unique to the TGF-beta mechanism.

Business Segments and Product Lines:

• Lead Program (Fisera First Alpha): An EGFR/TGF-beta trap antibody currently in a pivotal study for recurrent metastatic head and neck cancer.
• Clinical Data Highlights: Phase 1 data shows response rates nearly tripled compared to standard of care; median overall survival for HPV-negative patients is ~22 months (10 months vs. standard of care); twice as many patients alive at the 3-year mark compared to Keytruda.
• Fortify Flex Trial: A Phase 2/3 expansion study investigating a de-escalated dosing schedule (transitioning from weekly to every 3 weeks after 12 weeks of induction) to improve convenience and potentially tolerability while maintaining efficacy.
• Colorectal Cancer: Investigating the drug in the 3rd line plus setting; aiming to demonstrate safety and efficacy benchmarks (targeting 10-15% response rates to validate potential for earlier lines) and assess tolerability for future combination strategies.
• Target Population Strategy: The pivotal trial focuses exclusively on the HPV-negative population (approx. 18,000 U.S. patients with CPS >1), excluding HPV-positive patients who are anticipated to derive less benefit.

Market and Competitive Landscape:

• Genmab (Pidotumomab): Management interprets Genmab's Phase 3 data as consistent with historical controls (Pembrolizumab) in a blended population. They project Pidotumab's OS hazard ratio may deteriorate over time as the HPV-positive population (who live longer) dilutes the signal, suggesting a weaker tail effect compared to Bicara.
• J&J (Amivantamab + Chemotherapy + Pembrolizumab): Critiqued the recent triplet regimen data for lacking rapid tumor debulking (time-to-response >9 weeks vs. 6 weeks for Bicara), identical PFS to the dual therapy arm (~7 months vs. 9.9 months for Bicara), and high toxicity (26% discontinuation rate).
• Merck (Keytruda): Identified as the standard of care comparator; Bicara aims to significantly expand the responder population and duration of response beyond Keytruda's limitations.
• Market Differentiation: Bicara differentiates via rapid response speed, deep tumor reduction (80%+ in majority of responders), and durable "tail" effects on overall survival curves.

Risks and Challenges:

• Competitive Approval: Uncertainty regarding the initial label approval for competing TGF-beta agents (e.g., Genmab) and the potential for the market to shift if survival benefits are not sustained over time.
• Second-Line Competition: J&J's accelerated approval of Amivantamab in the second-line setting poses a potential risk for patients progressing in the Fortify trial, though management views this impact as limited to a small subset of U.S. patients.
• Toxicity Management: TGF-beta associated AEs (e.g., anemia, mucosal bleeding) are observed in deep responders and may be mitigated by the proposed less frequent dosing schedule in the Fortify Flex trial.
• Clinical Execution: The ability to achieve a statistically significant OS benefit with a smaller sample size relies on the faster accrual of death events in the HPV-negative population compared to Genmab's broader trial.

Management Commentary and Tone:

• Tone: Highly confident and strategic. Management expressed strong conviction in the drug's unique mechanism (depth and durability) and the validity of their exclusive focus on the HPV-negative population.
• Strategic Focus: Emphasized that the "war is not won on top-line data releases" but on securing a robust label that drives long-term adoption.
• Operational Control: Management stressed focusing on what they can control, specifically the execution of the Fortify trial, rather than reacting to competitor headline data.

Analyst Questions and Answers:

• Question: How does Genmab's Phase 3 data compare to Bicara's profile?
  • Answer: Genmab's data likely reflects a blended HPV+/HPV- population. In an HPV-negative subset, Pidotumab would likely show response rates in the mid-50s to low-60s. The survival hazard ratio may deteriorate as the trial matures due to the "survivor bias" of HPV-positive patients.
• Question: When will the OS interim analysis occur?
  • Answer: Timing is not fixed; it depends on the blinded accrual of death events in the HPV-negative cohort. The strategy prioritizes having data to inform regulatory strategy before the top-line readout.
• Question: What is the rationale for the Fortify Flex de-escalation study?
  • Answer: To maintain efficacy while improving administration convenience (every 3 weeks) and potentially reducing late-stage toxicity caused by high exposure after tumor debulking.
• Question: What impact does J&J's Amivantamab second-line approval have?
  • Answer: Minimal impact expected; the majority of Fortify enrollment is non-U.S. and patients on the trial likely already progressed on PD-1/Chemo regimens before Amivantamab became available.
• Question: What are the efficacy benchmarks for the Colorectal indication?
  • Answer: Targeting response rates of 10-15% to validate the mechanism; the critical success factor is demonstrating a tolerable profile to allow expansion into earlier lines of therapy.

Other Key Points:

• The company observed a median time-to-response of 6 weeks for Fisera First Alpha, compared to >9 weeks for J&J's triplet regimen.
• In the HPV-negative phase 1 cohort, 12 of 15 responders achieved a tumor reduction of 80% or greater, correlating with superior overall survival.
• The Fortify Flex trial endpoint requires the point estimate of the every-3-week arm to sit within the confidence interval of the weekly arm at the 24-week landmark.
• Preliminary signals in the CRC program suggest potential efficacy even in patients with liver metastases, a population typically associated with poor outcomes.